Parag Bawaskar
@paragbawaskar.bsky.social
Cardiologist, Post Doctoral Research Associate, Cardiovascular Division, University of Minnesota Medical School.
An important trial related to this topic was just funded in the UK – Peter Swoboda at the University of Leeds is the PI of an RCT to identify the best initial test for newly diagnosed HF… we look forward to the results of CROSS-HF in a few years.
November 11, 2023 at 4:22 AM
An important trial related to this topic was just funded in the UK – Peter Swoboda at the University of Leeds is the PI of an RCT to identify the best initial test for newly diagnosed HF… we look forward to the results of CROSS-HF in a few years.
We need to investigate whether NICM or dualCM in patients with CAD influences outcomes after coronary revascularization.
An ancillary study of the STICH3C trial by Mario Gaudino and Jonathan Weinsaft at Cornell will give us some answers in about 5 years.
An ancillary study of the STICH3C trial by Mario Gaudino and Jonathan Weinsaft at Cornell will give us some answers in about 5 years.
November 11, 2023 at 4:21 AM
We need to investigate whether NICM or dualCM in patients with CAD influences outcomes after coronary revascularization.
An ancillary study of the STICH3C trial by Mario Gaudino and Jonathan Weinsaft at Cornell will give us some answers in about 5 years.
An ancillary study of the STICH3C trial by Mario Gaudino and Jonathan Weinsaft at Cornell will give us some answers in about 5 years.
And we looked at their long-term outcomes.
Patients with CAD+NICM or dualCM had a greater risk of all-cause death or heart failure hospitalization, all-cause death, and heart failure hospitalization compared with CAD+ICM.
The risk of CV death was not different.
Patients with CAD+NICM or dualCM had a greater risk of all-cause death or heart failure hospitalization, all-cause death, and heart failure hospitalization compared with CAD+ICM.
The risk of CV death was not different.
November 11, 2023 at 4:20 AM
And we looked at their long-term outcomes.
Patients with CAD+NICM or dualCM had a greater risk of all-cause death or heart failure hospitalization, all-cause death, and heart failure hospitalization compared with CAD+ICM.
The risk of CV death was not different.
Patients with CAD+NICM or dualCM had a greater risk of all-cause death or heart failure hospitalization, all-cause death, and heart failure hospitalization compared with CAD+ICM.
The risk of CV death was not different.
We found NICM or dualCM in 1 of every 6 patients with CAD.
CAD+NoCM - 18.2%
CAD+ICM - 64.8%
CAD+NICM - 9.3%
CAD+dualCM - 7.7%
The prevalence of CAD+NICM or dualCM was 16.9% or 1 in 6 patients with CAD.
CAD+NoCM - 18.2%
CAD+ICM - 64.8%
CAD+NICM - 9.3%
CAD+dualCM - 7.7%
The prevalence of CAD+NICM or dualCM was 16.9% or 1 in 6 patients with CAD.
November 11, 2023 at 4:13 AM
We found NICM or dualCM in 1 of every 6 patients with CAD.
CAD+NoCM - 18.2%
CAD+ICM - 64.8%
CAD+NICM - 9.3%
CAD+dualCM - 7.7%
The prevalence of CAD+NICM or dualCM was 16.9% or 1 in 6 patients with CAD.
CAD+NoCM - 18.2%
CAD+ICM - 64.8%
CAD+NICM - 9.3%
CAD+dualCM - 7.7%
The prevalence of CAD+NICM or dualCM was 16.9% or 1 in 6 patients with CAD.
We looked at their CMRs and coronary angiography data and classified them into one of:
1. No cardiomyopathy (CAD+NoCM) – normal LVEF and no LGE
2. Ischemic cardiomyopathy (CAD+ICM)
3. Non-ischemic cardiomyopathy (CAD+NICM)
4. Dual cardiomyopathy (CAD+dualCM) – both ICM and NICM
1. No cardiomyopathy (CAD+NoCM) – normal LVEF and no LGE
2. Ischemic cardiomyopathy (CAD+ICM)
3. Non-ischemic cardiomyopathy (CAD+NICM)
4. Dual cardiomyopathy (CAD+dualCM) – both ICM and NICM
November 11, 2023 at 4:13 AM
We looked at their CMRs and coronary angiography data and classified them into one of:
1. No cardiomyopathy (CAD+NoCM) – normal LVEF and no LGE
2. Ischemic cardiomyopathy (CAD+ICM)
3. Non-ischemic cardiomyopathy (CAD+NICM)
4. Dual cardiomyopathy (CAD+dualCM) – both ICM and NICM
1. No cardiomyopathy (CAD+NoCM) – normal LVEF and no LGE
2. Ischemic cardiomyopathy (CAD+ICM)
3. Non-ischemic cardiomyopathy (CAD+NICM)
4. Dual cardiomyopathy (CAD+dualCM) – both ICM and NICM
We did a large retrospective observational study of 3,023 patients with obstructive CAD who had CMR for any clinical indication at our health system.
November 11, 2023 at 4:12 AM
We did a large retrospective observational study of 3,023 patients with obstructive CAD who had CMR for any clinical indication at our health system.
There has been interest in this topic of late because trials of coronary revascularization other than STICHES have not shown revascularization to be beneficial.
November 11, 2023 at 4:11 AM
There has been interest in this topic of late because trials of coronary revascularization other than STICHES have not shown revascularization to be beneficial.
Currently, we determine the cause of cardiomyopathy based on coronary angiography findings… CAD=ICM; No CAD=NICM
However, pathology and small CMR studies have shown that
NICM can occur with “bystander” CAD
ICM can occur without CAD
Both ICM and NICM can occur together
However, pathology and small CMR studies have shown that
NICM can occur with “bystander” CAD
ICM can occur without CAD
Both ICM and NICM can occur together
November 11, 2023 at 4:10 AM
Currently, we determine the cause of cardiomyopathy based on coronary angiography findings… CAD=ICM; No CAD=NICM
However, pathology and small CMR studies have shown that
NICM can occur with “bystander” CAD
ICM can occur without CAD
Both ICM and NICM can occur together
However, pathology and small CMR studies have shown that
NICM can occur with “bystander” CAD
ICM can occur without CAD
Both ICM and NICM can occur together
Have you ever wondered whether your patient with CAD and cardiomyopathy truly has ischemic cardiomyopathy, or whether the CAD is a “bystander”?
You might be interested in our paper now out in Circulation
#simultaneouspublication
#AHA23
#cardiosky
#Medsky
#WhyCMR
You might be interested in our paper now out in Circulation
#simultaneouspublication
#AHA23
#cardiosky
#Medsky
#WhyCMR
November 11, 2023 at 4:09 AM
Have you ever wondered whether your patient with CAD and cardiomyopathy truly has ischemic cardiomyopathy, or whether the CAD is a “bystander”?
You might be interested in our paper now out in Circulation
#simultaneouspublication
#AHA23
#cardiosky
#Medsky
#WhyCMR
You might be interested in our paper now out in Circulation
#simultaneouspublication
#AHA23
#cardiosky
#Medsky
#WhyCMR